To include your compound in the COVID-19 Resource Center, submit it here.

bioMerieux Pierre Fabre Group, IDM SA deal

bioMerieux division Pierre Fabre Medicament will provide Immuno-Designed access to a membrane fraction

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE